Bacterial Infections and Mycoses
Coccidioidomycosis
Infection with a fungus of the genus COCCIDIOIDES, endemic to the SOUTHWESTERN UNITED STATES. It is sometimes called valley fever but should not be confused with RIFT VALLEY FEVER. Infection is caused by inhalation of airborne, fungal particles known as arthroconidia, a form of FUNGAL SPORES. A primary form is an acute, benign, self-limited respiratory infection. A secondary form is a virulent, severe, chronic, progressive granulomatous disease with systemic involvement. It can be detected by use of COCCIDIOIDIN.
Antifungal Agents
Chromoblastomycosis
Scaly papule or warty growth, caused by five fungi, that spreads as a result of satellite lesions affecting the foot or leg. The extremity may become swollen and, at its distal portion, covered with various nodular, tumorous, verrucous lesions that resemble cauliflower. In rare instances, the disease may begin on the hand or wrist and involve the entire upper extremity. (Arnold, Odom, and James, Andrew's Diseases of the Skin, 8th ed, p362)
Histoplasmosis
Blastomycosis
A fungal infection that may appear in two forms: 1, a primary lesion characterized by the formation of a small cutaneous nodule and small nodules along the lymphatics that may heal within several months; and 2, chronic granulomatous lesions characterized by thick crusts, warty growths, and unusual vascularity and infection in the middle or upper lobes of the lung.
Paracoccidioidomycosis
Arthrodermataceae
Sporotrichosis
Zygomycosis
Infection in humans and animals caused by fungi in the class Zygomycetes. It includes MUCORMYCOSIS and entomophthoramycosis. The latter is a tropical infection of subcutaneous tissue or paranasal sinuses caused by fungi in the order Entomophthorales. Phycomycosis, closely related to zygomycosis, describes infection with members of Phycomycetes, an obsolete classification.
Candidiasis
Invasive Pulmonary Aspergillosis
Amphotericin B
Fungi
A kingdom of eukaryotic, heterotrophic organisms that live parasitically as saprobes, including MUSHROOMS; YEASTS; smuts, molds, etc. They reproduce either sexually or asexually, and have life cycles that range from simple to complex. Filamentous fungi, commonly known as molds, refer to those that grow as multicellular colonies.
Meningitis, Fungal
Itraconazole
Opportunistic Infections
Trichophyton
Candida
A genus of yeast-like mitosporic Saccharomycetales fungi characterized by producing yeast cells, mycelia, pseudomycelia, and blastophores. It is commonly part of the normal flora of the skin, mouth, intestinal tract, and vagina, but can cause a variety of infections, including CANDIDIASIS; ONYCHOMYCOSIS; vulvovaginal candidiasis (CANDIDIASIS, VULVOVAGINAL), and thrush (see CANDIDIASIS, ORAL). (From Dorland, 28th ed)
Mycetoma
A chronic progressive subcutaneous infection caused by species of fungi (eumycetoma), or actinomycetes (actinomycetoma). It is characterized by tumefaction, abscesses, and tumor-like granules representing microcolonies of pathogens, such as MADURELLA fungi and bacteria ACTINOMYCETES, with different grain colors.
Sporothrix
Fluconazole
Trichosporon
Paracoccidioides
Onychomycosis
Aspergillus
AIDS-Related Opportunistic Infections
Opportunistic infections found in patients who test positive for human immunodeficiency virus (HIV). The most common include PNEUMOCYSTIS PNEUMONIA, Kaposi's sarcoma, cryptosporidiosis, herpes simplex, toxoplasmosis, cryptococcosis, and infections with Mycobacterium avium complex, Microsporidium, and Cytomegalovirus.
Candida albicans
Lung Diseases, Fungal
Mycology
Immunocompromised Host
Histoplasma
beta-Glucans
Meningitis, Cryptococcal
Meningeal inflammation produced by CRYPTOCOCCUS NEOFORMANS, an encapsulated yeast that tends to infect individuals with ACQUIRED IMMUNODEFICIENCY SYNDROME and other immunocompromised states. The organism enters the body through the respiratory tract, but symptomatic infections are usually limited to the lungs and nervous system. The organism may also produce parenchymal brain lesions (torulomas). Clinically, the course is subacute and may feature HEADACHE; NAUSEA; PHOTOPHOBIA; focal neurologic deficits; SEIZURES; cranial neuropathies; and HYDROCEPHALUS. (From Adams et al., Principles of Neurology, 6th ed, pp721-2)
Endemic Diseases
The constant presence of diseases or infectious agents within a given geographic area or population group. It may also refer to the usual prevalence of a given disease with such area or group. It includes holoendemic and hyperendemic diseases. A holoendemic disease is one for which a high prevalent level of infection begins early in life and affects most of the child population, leading to a state of equilibrium such that the adult population shows evidence of the disease much less commonly than do children (malaria in many communities is a holoendemic disease). A hyperendemic disease is one that is constantly present at a high incidence and/or prevalence rate and affects all groups equally. (Last, A Dictionary of Epidemiology, 3d ed, p53, 78, 80)
Echinocandins
Cyclic hexapeptides of proline-ornithine-threonine-proline-threonine-serine. The cyclization with a single non-peptide bond can lead them to be incorrectly called DEPSIPEPTIDES, but the echinocandins lack ester links. Antifungal activity is via inhibition of 1,3-beta-glucan synthase production of BETA-GLUCANS.
DNA, Ribosomal Spacer
Aspergillus fumigatus
Cryptococcus neoformans
Hematologic Neoplasms
Microbial Sensitivity Tests
Treatment of murine fusariosis with SCH 56592. (1/2265)
Doses of 10 to 100 mg of the azole antifungal agent SCH 5692/kg of body weight/day were studied in immunocompetent mice as therapy for systemic infection by Fusarium solani. Treatment was begun 1 h after intravenous infection and continued daily for 4 or 13 doses. Prolongation of survival and organ clearance were dependent on both the dose and the duration of SCH 56592 therapy, with the best results seen at 50 and 100 mg/kg/day. The results at the highest doses of SCH 56592 used (50 or 100 mg/kg/day) were comparable to those obtained with amphotericin B at 1 mg/kg/day. SCH 56592 has potential for therapy of systemic infections caused by F. solani. (+info)In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. (2/2265)
The in-vitro fungistatic and fungicidal activities of voriconazole were compared with those of itraconazole and amphotericin B. MICs for 110 isolates belonging to 11 species of filamentous fungi were determined by a broth microdilution adaptation of the method recommended by the National Committee for Clinical Laboratory Standards. Minimum lethal concentrations (MLCs) of the three antifungal agents were also determined. The MIC ranges of the three compounds were comparable for Aspergillus flavus, Aspergillus fumigatus, Cladophialophora bantiana and Exophiala dermatitidis. Voriconazole and itraconazole were more active than amphotericin B against Fonsecaea pedrosoi, but the two azole agents were less active against Sporothrix schenckii. Voriconazole was more active than itraconazole or amphotericin B against Scedosporium apiospermum, but less active than the other two agents against two mucoraceous moulds, Absidia corymbifera and Rhizopus arrhizus. Voriconazole and amphotericin B were more active than itraconazole against Fusarium solani. With the exception of S. apiospermum, all the moulds tested had MLC50 values of < or =2 mg/L and MLC90 values of < or =4 mg/L against amphotericin B. Voriconazole and itraconazole showed fungicidal effects against five of the 1 1 moulds tested (A. flavus, A. fumigatus, C. bantiana, E. dermatitidis and F. pedrosoi) with MLC90 values of < or =2 mg/L. In addition, voriconazole was fungicidal for Phialophora parasitica. Our results suggest that voriconazole could be effective against a wide range of mould infections in humans. (+info)In-vivo therapeutic efficacy in experimental murine mycoses of a new formulation of deoxycholate-amphotericin B obtained by mild heating. (3/2265)
Heat-induced 'superaggregation' of deoxycholate-amphotericin B (AmB-DOC, Fungizone) was shown previously to reduce the in-vitro toxicity of this antifungal agent. We compared AmB-DOC with the formulation obtained by heating the commercial form (Fungizone, Bristol Myers Squibb, Paris, France) for 20 min at 70 degrees C, in the treatment of murine infections. An improvement of antifungal activity was obtained with heated AmB-DOC formulations due to a lower toxicity which allowed the administration of higher drug doses than those achievable with the commercial preparation. Single intravenous injections of heated AmB-DOC solutions were demonstrated to be two-fold less toxic than unheated ones to healthy mice. For mice infected with Candida albicans, the maximum tolerated dose was higher with heated than with unheated AmB-DOC solutions. In the model of murine candidiasis, following a single dose of heated AmB-DOC 0.5 mg/kg, 85% of mice survived for 3 weeks, whereas at this dose the immediate toxicity of the standard formulation in infected mice restricted the therapeutic efficacy to 25% survival. Both formulations were equally effective in increasing the survival time for murine cryptococcal pneumonia and meningoencephalitis. Injection of heated AmB-DOC solutions at a dose two-fold higher than the maximal tolerated dose observed with the unheated preparation (1.2 mg/kg) increased the survival time by a factor of 1.4 in cryptococcal meningoencephalitis. These results indicate that mild heat treatment of AmB-DOC solutions could provide a simple and economical method to improve the therapeutic index of this antifungal agent by reducing its toxicity on mammalian cells. (+info)Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto. (4/2265)
To evaluate the efficacy and safety of itraconazole oral solution for preventing fungal infections, a randomized, placebo-controlled, double-blind, multicenter trial was conducted: 405 neutropenic patients with hematologic malignancies were randomly assigned to receive either itraconazole, 2.5 mg/kg every 12 hours (201 patients), or placebo (204 patients). Proven and suspected deep fungal infection occurred in 24% of itraconazole recipients and in 33% of placebo recipients, a difference of 9 percentage points (95% confidence interval [CI], 0.6% to 22.5%; P = .035). Fungemia due to Candida species was documented in 0.5% of itraconazole recipients and in 4% of placebo recipients, a difference of 3.5 percentage points (95% CI, 0.5% to 6%; P = .01). Deaths due to candidemia occurred in none of the itraconazole recipients compared with 4 placebo recipients, a difference of 2 percentage points (95% CI, 0.05% to 4%; P = .06). Aspergillus infection was documented in four itraconazole recipients (one death) and one placebo recipient (one death). Side effects causing drug interruption occurred in 18% of itraconazole recipients and 13% of placebo recipients. Itraconazole oral solution was well-tolerated and effectively prevented proven and suspected deep fungal infection as well as systemic infection and death due to Candida species. (+info)Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. (5/2265)
A randomized, double-blind trial comparing oral fluconazole (400 mg daily) with placebo as prophylaxis for adult patients receiving intensive cytotoxic therapy for acute leukemia or autologous bone marrow transplantation was conducted in 14 Canadian university-affiliated hospitals. Although fluconazole prophylaxis did not obviate the need for parenteral antifungal therapy compared with placebo (81 [57%] of 141 vs. 67 [50%] of 133, respectively), its use resulted in fewer superficial fungal infections (10 [7%] of 141 vs. 23 [18%] of 131, respectively; P = .02) and fewer definite and probable invasive fungal infections (9 vs. 32, respectively; P = .0001). Fluconazole recipients had fewer deaths attributable to definite invasive fungal infection (1 of 15 vs. 6 of 15, respectively; P = .04) and achieved more frequent success without fungal colonization (52 [37%] of 141 vs. 27 [20%] of 133, respectively; P = .004; relative risk reduction, 85%) than did placebo recipients. Patients benefiting the most from fluconazole prophylaxis included those with acute myeloid leukemia who were undergoing induction therapy with cytarabine plus anthracycline-based regimens and those receiving marrow autografts not supported with hematopoietic growth factors. Fluconazole prophylaxis reduces the incidence of superficial fungal infection and invasive fungal infection and fungal infection-related mortality among patients who are receiving intensive cytotoxic chemotherapy for remission induction. (+info)Phycomycotic gastritis in buffalo calves (Bubalis bubalis). (6/2265)
Mycotic gastritis, primarily caused by Rhizopus sp. was seen in six buffalo calves (7-13 days old) at postmortem examination. The predominant lesions were numerous raised ulcers in which were hyphae of Rhizopus. In three calves, Candida organisms were also present superficially in the ulcers. Other changes in the mucosa were severe congestion, haemorrhage, thrombosis, necrosis, and infiltration by lymphocytes and neutrophils. Both Rhizopus and Candida were highly pathogenic to rabbits when inoculated intravenously. The disease could not be reproduced experimentally by feeding of Rhizopus orally to rabbits and calves. (+info)Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. (7/2265)
BACKGROUND: In patients with persistent fever and neutropenia, amphotericin B is administered empirically for the early treatment and prevention of clinically occult invasive fungal infections. However, breakthrough fungal infections can develop despite treatment, and amphotericin B has substantial toxicity. METHODS: We conducted a randomized, double-blind, multicenter trial comparing liposomal amphotericin B with conventional amphotericin B as empirical antifungal therapy. RESULTS: The mean duration of therapy was 10.8 days for liposomal amphotericin B (343 patients) and 10.3 days for conventional amphotericin B (344 patients). The composite rates of successful treatment were similar (50 percent for liposomal amphotericin B and 49 percent for conventional amphotericin B) and were independent of the use of antifungal prophylaxis or colony-stimulating factors. The outcomes were similar with liposomal amphotericin B and conventional amphotericin B with respect to survival (93 percent and 90 percent, respectively), resolution of fever (58 percent and 58 percent), and discontinuation of the study drug because of toxic effects or lack of efficacy (14 percent and 19 percent). There were fewer proved breakthrough fungal infections among patients treated with liposomal amphotericin B (11 patients [3.2 percent]) than among those treated with conventional amphotericin B (27 patients [7.8 percent], P=0.009). With the liposomal preparation significantly fewer patients had infusion-related fever (17 percent vs. 44 percent), chills or rigors (18 percent vs. 54 percent), and other reactions, including hypotension, hypertension, and hypoxia. Nephrotoxic effects (defined by a serum creatinine level two times the upper limit of normal) were significantly less frequent among patients treated with liposomal amphotericin B (19 percent) than among those treated with conventional amphotericin B (34 percent, P<0.001). CONCLUSIONS: Liposomal amphotericin B is as effective as conventional amphotericin B for empirical antifungal therapy in patients with fever and neutropenia, and it is associated with fewer breakthrough fungal infections, less infusion-related toxicity, and less nephrotoxicity. (+info)Detection of cell wall mannoprotein Mp1p in culture supernatants of Penicillium marneffei and in sera of penicilliosis patients. (8/2265)
Mannoproteins are important and abundant structural components of fungal cell walls. The MP1 gene encodes a cell wall mannoprotein of the pathogenic fungus Penicillium marneffei. In the present study, we show that Mp1p is secreted into the cell culture supernatant at a level that can be detected by Western blotting. A sensitive enzyme-linked immunosorbent assay (ELISA) developed with antibodies against Mp1p was capable of detecting this protein from the cell culture supernatant of P. marneffei at 10(4) cells/ml. The anti-Mp1p antibody is specific since it fails to react with any protein-form lysates of Candida albicans, Histoplasma capsulatum, or Cryptococcus neoformans by Western blotting. In addition, this Mp1p antigen-based ELISA is also specific for P. marneffei since the cell culture supernatants of the other three fungi gave negative results. Finally, a clinical evaluation of sera from penicilliosis patients indicates that 17 of 26 (65%) patients are Mp1p antigen test positive. Furthermore, a Mp1p antibody test was performed with these serum specimens. The combined antibody and antigen tests for P. marneffei carry a sensitive of 88% (23 of 26), with a positive predictive value of 100% and a negative predictive value of 96%. The specificities of the tests are high since none of the 85 control sera was positive by either test. (+info)
Cutaneous manifestations of deep fungal infections in HIV disease<...
Invasive fungal infection - Symptoms, Treatments and Resources for Invasive fungal infection
Fluorescence of fungi in superficial and deep fungal infections | BMC Microbiology | Full Text
Caspofungin Based Combined Anti-fungal Therapy for Proven or Probable Invasive Fungal Infection - Full Text View -...
Reticuloendothelial phagocytic function during systemic mycotic infections in man<...
Caspofungin Based Combined Anti-fungal Therapy for Proven or Probable Invasive Fungal Infection
Immune defence to invasive fungal infections: A comprehensive review. - Aspergillus and Aspergillosis
北京大学医学部机构知识库([email protected]): Epidemiology, Management, and Outcome of Invasive Fungal Disease in Patients Undergoing Hematopoietic...
A Prospective Observational Multi-institutional Study on Invasive Fungal Infections Following Chemotherapy for Acute Myeloid...
Epidemiology and treatment approaches in management of invasive fungal infections in hematological malignancies: Results from a...
Invasive fungal diseases in patients with acute leukemia or allogeneic stem cell transplantion recepients: A prospective...
Management of Invasive Fungal Disease in Neonates and Children
The Journal of Invasive Fungal Infections - Volume 4 Issue 3 - Genetic Polymorphisms and Susceptibility to Fungal Infections
The direct cost and incidence of systemic fungal infections
PK/PD Study of Posaconazole for Empiric Treatment of Invasive Fungal Infections in Neutropenic Patients or Treatment of...
Diflucan systemic fungal infection
IJMS | Free Full-Text | Invasive Fungal Infections in Patients with Hematologic Malignancies (Aurora Project): Lights and...
Molecular Mycology: Current Approaches to Fungal Pathogenesis
Systemic Mycoses and Atypical Organisms | Washington Manual of Medical Therapeutics
Systemic Mycoses Sales Market by Scientific Reviews,Clinical Application 2017
Invasive Fungal Infections in HSCT Recipients: Improving Outcomes Through Prevention and Treatment
Review: Voriconazole for prevention or treatment of invasive fungal infections in cancer with neutropenia | Annals of Internal...
Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the...
Application of Radioisotopes in Anti-Fungal Research and Fungal Disease Studies | Bentham Science
Fungal infections in the pediatric cancer patient<...
Skin Allergic Testing in Pulmonary Mycotic Infection
Click to print
Mycoses News, Research Articles | Fungal Infection Clinical Studies
Pneumonia (Fungal) in Dogs | petMD
Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell...
Mycoses -- Immunotherapy (Concept) - Rensselaer Libraries
OPPORTUNISTIC MYCOSES - ppt video online download
Mycoses | 2017(06) articles
Recherches Exprimentales Sur Les Mycoses Internes
Invasive fungal infections in the intensive care unit: a multicentre, prospective, observational study in Italy (2006-2008). -...
Fungal Infections - Protect Your Health | Fungal Diseases | CDC
Aspergillus | Profiles RNS
Fungal infections caused by spp. 70% of these cases are caused | Small molecule inhibitors of HCV replication
CHAPTER 14- PARASITIC & FUNGAL INFECTIONS - ppt download
Fungal Infections: Causes and treatment | Health Tips
SCYNEXIS Expands FURI Protocol to a Broader Range of Refractory Serious Fungal Infections, Building on Ibrexafungerps Positive...
What Is Blood Fungus? | Healthy Living
Enlarged circumvallate papillae with yeast infection. Causes?
Severe Fungal Infections
Diagnosis of fungal infections - کتابخانه دیجیتالی دانشگاه علوم پزشکی و خدمات درمانی شهید بهشتی
Fungal Infection Treatments Arlington VA - breast cancer drug, Arlington VA fungal infection, Arlington VA cancer treatment,...
systemic fungal | Answers from Doctors | HealthTap
Search Articles | University of Toronto Libraries
phagocytosis | mBio
Penicillium Marneffei Infection | What is it?
Trichoderma longibrachiatum - Wikipedia
Rapid and precise diagnosis of disseminated T.marneffei infection assisted by high-throughput sequencing of multifarious...
Invasive fungal disease in humans: Are we aware of the real impact?<...
Infección sistémica por Paecilomyces lilacinus en un paciente inmunodeprimido pediátrico: Report of one case
Mixed treatment comparison of prophylaxis against invasive fungal infections in neutropenic patients receiving therapy for...
Clinical characteristics and outcome of Penicillium marneffei infection among HIV-infected patients in northern Vietnam
Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview...
A Randomized Trial of Caspofungin vs Triazoles Prophylaxis for Invasive Fungal Disease in Pediatric Allogeneic Hematopoietic...
CME Preventing and Managing Cytomegalovirus and Invasive Fungal Infection After Hematopoietic Stem Cell Transplantation: Key...
Bioline International Official Site (site up-dated regularly)
Mycoses | Article about Mycoses by The Free Dictionary
PPT - Fungi & Systemic Mycoses PowerPoint presentation | free to download - id: 3bf4ec-MTM1Z
ECMM Certification of the University Hospital of Cologne as Excellence Center (EC), 10 October, 2017 | ECMM
45: Fungal infections
The Use of Combination Antifungal Therapy is Not a Black and White Issue
Invasive Fungal Infections In Liver Transplant Patients - Doug Kaufmanns Know the Cause
Most recent papers with the keyword Msg | Read by QxMD
House Call: Fungal infections stubborn, treatable | The Spokesman-Review
Vaccines and immunotherapy against fungi: the new frontier | Frontiers Research Topic
Systemic fungal infections caused by Candida species: epidemiology, infection process and virulence attributes
Unscramble mycology | Words unscrambled from letters mycology | Scrabble Word mycology | Words Made with the Letters mycology
Selected Publications | MRC Centre for Medical Mycology | University of Exeter
The major causes of yeast infections
Allergic Fungal Sinusitis | Health Knowledge Profession
Fungal Diseases of Plants | Article about Fungal Diseases of Plants by The Free Dictionary
Genital Itching - Yeast Infection or Allergy? | Itchy Vagina
The systemic mycoses - photos
Emerging IL-12 family cytokines in the fight against fungal infections -ORCA
Plus it
NCT00002038 | Candidiasis, Mycoses, HIV Infections Clinical Trial | Pfizer
Overview and Types of Fungal Infections | News Ghana
Atlas of Fungal Infection
The laboratory working party - EAPCRI
Welcome to CDC stacks | Emerging issues, challenges, and changing epidemiology of fungal disease outbreaks - 50454 | CDC Public...
Lyman, C.A., Devi, S.J., Nathanson, J., Frasch, C.E., Pizzo, P.A. and Walsh, T.J. (1995) Detection and Quantitation of the...
Treatment of Fungal Infections of Sinuses
2011 ICD-9-CM Diagnosis Code V75.4 : Screening examination for mycotic infections
MCQ on Superficial and Cutaneous Mycoses (Medical Mycology)
Optimal Use of the Newer Antifungal Agents | Cancer Network | The Oncology Journal
Professor Gordon Brown - Mycology 2020
Mycology Laboratory
Mycology Laboratory
Neglected tropical diseases
Chromoblastomycosis and other deep mycoses, scabies and other ectoparasites and snakebite envenoming were added to the list in ...
Black yeast
Mycoses. 45 (9-10): 373-7. doi:10.1046/j.1439-0507.2002.00779.x. PMID 12421284. S2CID 4842988. Gorbushina, A.A.; Kotlova, E.R ...
Lyubov Yablochnik
Yablochnik's postgraduate study in the laboratory of mycology and antibiotics at VIEV led to her work on mycoses (diseases of ... In 1978, she led development of a new laboratory for the control and standardization of preparations against mycoses and she ... Rybnikář, A; Chumela, J; Vrzal, V; Krupka, V (1991). "Immunity in cattle vaccinated against ringworm". Mycoses. 34 (9-10): 433- ... Mycoses. 57 (7): 400-405. doi:10.1111/myc.12174. PMID 24621382. S2CID 25324021.CS1 maint: multiple names: authors list (link) ...
Aphanoascus fulvescens
Cano J. Guarro J, Figueras M. (March 1991). "Study of the invasion of human hair in vitro by Aphanoascus spp." Mycoses. 34(3): ... Cano J, Guarro J, Mayayo J. (January 1990). "Experimental Pathogenicity of Aphanoascus spp.". Mycoses 33(1): 41-45. de Vries G ...
Geomyces pannorum
pannorum". Mycoses. 46 (9-10): 430-432. doi:10.1046/j.1439-0507.2003.00897.x. PMID 14622395. Christen-Zaech, S; Patel, S; ...
Sagenomella
Jand SK, Gupta MP (1989). "Dermatomycosis in dogs". Mycoses. 32 (2): 104-5. doi:10.1111/j.1439-0507.1989.tb02213.x. PMID ...
TALE-likes
Mycoses. 51 (3): 266-9. doi:10.1111/j.1439-0507.2007.01477.x. PMID 18399908. Yooseph S, Sutton G, Rusch DB, Halpern AL, ...
Keratinophyton durum
Mycoses. 38 (3-4): 163-166. doi:10.1111/j.1439-0507.1995.tb00042.x. ISSN 0933-7407. "Keratinophyton durum". www.mycobank.org. ...
Tagetes patula
Mycoses. 50 (2): 121-124. doi:10.1111/j.1439-0507.2006.01332.x. PMID 17305775. Mares D, Tosi B, Poli F, Andreotti E, Romagnoli ...
Cladosporium oxysporum
Cutaneous phaeohyphomycosis caused by Cladosporium oxysporum". Mycoses. 42 (1-2): 111-115. doi:10.1046/j.1439-0507.1999.00263.x ...
Chrysosporium keratinophilum
Mycoses. 42 (4): 339-343. doi:10.1046/j.1439-0507.1999.00457.x. Ali-Shtayeh, M. S. (September 1988). "Keratinophilic fungi ... Mycoses. 35 (3-4): 95-97. doi:10.1111/j.1439-0507.1992.tb00826.x. Singh, I.; Dixit, A. K.; Kushwaha, R. K. S. (January 2010). " ... "Antagonism of Microsporum species by soil fungi". Mycoses. 53 (1): 32-39. doi:10.1111/j.1439-0507.2008.01656.x. PMID 19207833. ...
Tinea versicolor
Mycoses. 50 (1): 58-63. doi:10.1111/j.1439-0507.2006.01310.x. PMID 17302750. Weedon, D. (2002). Skin pathology (2nd ed.). ...
Arthrographis kalrae
Mycoses. 57 (4): 247-8. doi:10.1111/myc.12151. PMID 24147779. LA, nagashima (2016). "Immunomodulation over the course of ...
2-Hydroxyisocaproic acid
Mycoses. 57 (4): 214-21. doi:10.1111/myc.12145. PMID 24125484. S2CID 24106682. Lang, Charles H.; Pruznak, Anne; Navaratnarajah ...
Microsporum nanum
Mycoses. 54 (2): 179-181. doi:10.1111/j.1439-0507.2009.01776.x. Mahmoud, DA; Hassanein NM; Youssef KA; Abou Zeid MA (July 2011 ...
Trichophyton verrucosum
"Epidemiological trends in skin mycoses worldwide". Mycoses. 51: 2-15. doi:10.1111/j.1439-0507.2008.01606.x. PMID 18783559. ... Beneke, E., Rogers, A. (1996). Medical Mycology and Human Mycoses. California: Star. pp. 85-90. ISBN 0-89863-175-0.CS1 maint: ... Mycoses. 57 (7): 400-405. doi:10.1111/myc.12174. PMID 24621382. S2CID 25324021.CS1 maint: multiple names: authors list (link) ... Mycoses. 54 (6): 870-876. doi:10.1111/j.1439-0507.2011.02015.x. PMID 21615536. S2CID 20736796.CS1 maint: multiple names: ...
Sporotrichosis
Lortholary O, Denning DW, Dupont B (March 1999). "Endemic mycoses: a treatment update". The Journal of Antimicrobial ... Mycoses. 47 (1-2): 62-8. doi:10.1046/j.1439-0507.2003.00953.x. PMID 14998402. Takahashi S, Masahashi T, Maie O (October 1981 ...
Mucor mucedo
Lee, Soo Chan; Heitman, Joseph (December 2014). "Sex in the Mucoralean Fungi". Mycoses. 57: 18-24. doi:10.1111/myc.12244. PMC ...
Rhizomucor pusillus
Mycoses. 44:253-260. Ribes, J. A., C. L. Vanover-Sams, and D. J. Baker. 2000. Zygomycetes in human disease. Clin Microbiol Rev ...
Pseudallescheria boydii
Mycoses. 37 (3-4): 71-8. doi:10.1111/j.1439-0507.1994.tb00780.x. PMID 7845423. Figueiredo, Rodrigo Tinoco; Bittencourt, Vera ...
Chromoblastomycosis
Although the mycosis slowly spreads, it usually remains localized to the skin and subcutaneous tissue. Hematogenous and/or ... Chromoblastomycosis is a long-term fungal infection of the skin and subcutaneous tissue (a chronic subcutaneous mycosis). The ... Mycoses. 44 (1-2): 1-7. doi:10.1046/j.1439-0507.2001.00613.x. PMID 11398635. de Andrade TS, Cury AE, de Castro LG, Hirata MH, ...
Lanosterol 14 alpha-demethylase
Vanden Bossche H, Koymans L (1998). "Cytochromes P450 in fungi". Mycoses. 41 Suppl 1: 32-8. doi:10.1111/j.1439-0507.1998. ...
Trichosporon asteroides
Mycoses. 37 (1-2): 3-10. doi:10.1111/j.1439-0507.1994.tb00277.x. Anaissie, E.; Gokaslan, A.; Hachem, R.; Rubin, R.; Griffin, G ...
Phialophora verrucosa
Most strains of P. verrucosa available in culture collections are derived from human mycoses. P. verrucosa is a common cause of ... Duggan, J.M.; Wolf, M.D.; Kauffiman, C.A. (May 1995). "Phialophora verrucosa infection in an AIDS patient". Mycoses. 38 (5-6): ... Mycoses. 48 (6): 456-461. doi:10.1111/j.1439-0507.2005.01150.x. PMID 16262887. S2CID 28365592. Tendolkar, U.M.; Kerkar, P.; ...
Vaginal yeast infection
Mycoses. 55 Suppl 3: 1-13. doi:10.1111/j.1439-0507.2012.02185.x. PMID 22519657. S2CID 35082539. Gunter, Jen. The vagina bible ...
Alternaria tenuissima
Mycoses. 39 (5-6): 211-215. doi:10.1111/j.1439-0507.1996.tb00127.x. PMID 8909032. S2CID 20166266. Saenz-de-Santamaria, M.; ... Mycoses. 49 (2): 91-95. doi:10.1111/j.1439-0507.2006.01195.x. PMID 16466440. S2CID 24588508. Denning, David W; Pashley, ...
Amorolfine
Mycoses. 48 (2): 91-4. doi:10.1111/j.1439-0507.2004.01090.x. PMID 15743424. Feng X, Xiong X, Ran Y (May 2017). "Efficacy and ...
Fungus
Fungi portal Conservation of fungi Fantastic Fungi Marine fungi MycoBank Mycosis Outline of fungi Moore RT (1980). "Taxonomic ... Mycoses. 48 (6): 365-77. doi:10.1111/j.1439-0507.2005.01165.x. PMID 16262871. S2CID 1356254. Farrar JF (October 1985). " ...
Cladosporium sphaerospermum
Mycoses. 0 (1): 070726205023006--. doi:10.1111/j.1439-0507.2007.01417.x. PMID 18076601. S2CID 33166762. Davis, ND; Wagener, E; ...
Intermammary cleft
Mycoses. 50 (1): 58-63. doi:10.1111/j.1439-0507.2006.01310.x. PMID 17302750. S2CID 25493290. Likness, LP (June 2011). "Common ...
The superficial mycoses. - PubMed - NCBI
The superficial mycoses.. Assaf RR1, Weil ML.. Author information. 1. Center for Medical Mycology, Case Western Reserve ... The various agents of the superficial mycoses have been recognized for more than a century as causes of mild diseases affecting ... and treatment of the common skin presentation of these and the other superficial mycoses are reviewed. ...
Mycosis fungoides: MedlinePlus Genetics
Mycosis fungoides is the most common form of a type of blood cancer called cutaneous T-cell lymphoma. Explore symptoms, ... Mycosis fungoides is the most common form of a type of blood cancer called cutaneous T-cell lymphoma. Cutaneous T-cell ... The tumors in mycosis fungoides, which are composed of cancerous T cells, are raised nodules that are thicker and deeper than ... For unknown reasons, mycosis fungoides affects males nearly twice as often as females. In the United States, there are an ...
Mycoses (journal) - Wikipedia
... "mycoses"). It was originally published in German, but switched 1988 to English. At that time the title was changed to Mycoses. ... Mycoses: Diagnosis, Therapy and Prophylaxis of Fungal Diseases is a monthly peer-reviewed medical journal covering mycology. It ... "Mycoses". 2018 InCites Journal Citation Reports. Web of Science (Science ed.). Clarivate. 2018. Official website v t e. ...
Mycoses: Ingenta Connect Table Of Contents
Mycoses: Ingenta Connect Table Of Contents
Endemic mycoses: a treatment update
Amphotericin B remains the drug of choice during the acute stage of life-threatening endemic mycoses occurring in both ... Endemic mycoses remain a major public health problem in several countries and they are becoming increasingly frequent with the ... Endemic mycoses: a treatment update J Antimicrob Chemother. 1999 Mar;43(3):321-31. doi: 10.1093/jac/43.3.321. ... Endemic mycoses remain a major public health problem in several countries and they are becoming increasingly frequent with the ...
Mycosis - Wikipedia
Mycosis is an infectious disease caused by pathogenic fungus in humans and animals. Mycoses are common and a variety of ... mycoses B35-B49. "Dorlands Medical Dictionary:mycosis". "What Is a Fungal Infection?". Archived from the original on June 19, ... Examples of opportunistic mycoses include Candidiasis, Cryptococcosis and Aspergillosis.[citation needed] In ICD-10CM, mycoses ... Organisms that cause systemic mycoses are inherently virulent. In general, primary pathogens that cause systemic mycoses are ...
Mycoses - Volume 23, Issue 8 - August 1980 - Wiley Online Library
Orale Langzeitbehandlung von Onychomykosen mit Ketoconazol : Oral Long-Term Treatment of Onychomycoses with Ketoconazole (pages 405-415). J. Brugmans, H. Scheijgrond, J. Van Cutsem, H. Van den Bossche, A. Baisier and Ch. Hörig. Version of Record online: 24 APR 2009 , DOI: 10.1111/j.1439-0507.1980.tb02626.x. ...
SYSTEMIC MYCOSIS IN CHANNEL CATFISH*
mycosis fungoides [00520]
Skin Care Guidelines for Patients With Mycosis Fungoides
Mycosis fungoides is the most common form of cutaneous T-cell lymphoma within the general population. Lesions are most commonly ... Infection has been shown to function as a catalyst for further disease progression in mycosis fungoides, due to further ... mycosis fungoides patients are at an increased risk of Staphylococcus aureus infections due to their compromised immune systems ... pH balanced cleansers and limiting the duration of daily showers is of utmost importance to patients diagnosed with mycosis ...
NCCN Guidelines for Patients® | Mycosis Fungoides
NCCN Guidelines for Patients® | Mycosis Fungoides
48 NCCN Guidelines for Patients ® Mycosis Fungoides, Version 1.2016 3 DCIS Genetic counseling , Treatment 4 Treatment guide Stage III treatment 4.4 Stage III treatment See second- and third-line treatments, page 50. Þ Start with first-line treatments: Try another course of first-line treatments if: • Treatment worked at first but the cancer came back as stage I, II, or III, or • Only 1 or 2 treatments were tried and didnt work Chart 4.4.1 First-line treatments No blood Involvement • Topical steroids • Topical chemotherapy (ie, mechlorethamine) • Phototherapy • Total skin electron beam therapy Blood involvement • Systemic treatment ± skin treatment Systemic treatment ◦◦ Oral retinoids ◦◦ Interferons ◦◦ HDAC inhibitors (ie, belinostat,vorinostat, romidepsin) ◦◦ Extracorporeal photopheresis ◦◦ Methotrexate Skin treatment ◦◦ Topical steroids ◦◦ Mechlorethamine ◦◦ Local radiation ◦◦ Topical retinoids ◦◦ Phototherapy ◦◦ Topical imiquimod ...
Mycosis Fungoides - Trip Database
Helping you find trustworthy answers on Mycosis Fungoides , Latest evidence made easy ... Find all the evidence you need on Mycosis Fungoides via the Trip Database. ... Large Cell Transformation of Oral Mycosis Fungoides (PubMed). Large Cell Transformation of Oral Mycosis Fungoides Mycosis ... Hypopigmented Mycosis Fungoides Treated with 308 nm Excimer Laser (PubMed). Hypopigmented Mycosis Fungoides Treated with 308 nm ...
Mycosis Fungoides - Trip Database
Helping you find trustworthy answers on Mycosis Fungoides , Latest evidence made easy ... Find all the evidence you need on Mycosis Fungoides via the Trip Database. ... Risk Factors for Skin Infections in Mycosis Fungoides. (PubMed). Risk Factors for Skin Infections in Mycosis Fungoides. Mycosis ... Hypopigmented Mycosis Fungoides Treated with 308 nm Excimer Laser (PubMed). Hypopigmented Mycosis Fungoides Treated with 308 nm ...
Mycosis Fungoides
... , Cutaneous T-Cell Lymphoma, Sezary Syndrome, Sezary Cell, Sezary Erythroderma. ... mycosis fungoides NAO, mycoses fungoides, mycosis fungoides, Mycosis fungoides. French. Mycosis fongoïde SAI, MYCOSIS FUNGOIDE ... site, [M]Mycosis fungoides NOS, mycosis fungoides lymphoma, MYCOSIS FUNGOIDES, [M]Mycosis fungoides, mycosis fungoides, mycosis ... Mycosis fongoïde, Maladie dAlibert, Mycosis fungoïde. German. Mycosis fungoides NNB, Mycosis fungoides-Erkrankungen, Mycosis ...
Invasive Candida infections in the ICU - Eggimann - 2012 - Mycoses - Wiley Online Library
Mycoses | GreenMedInfo | Disease | Natural Medicine | Alternative
How is mycosis fungoides cutaneous T-cell lymphoma (CTCL) treated?
... are used to manage mycosis fungoides. Generally, topical therapies are indicated for stage I patient... more ... Two cases of mycosis fungoides treated by reduced-intensity cord blood transplantation. J Dermatol. 2010 Dec. 37(12):1040-5. [ ... Clinicoepidemiological features of mycosis fungoides in Kuwait, 1991-2006. Int J Dermatol. 2010 Dec. 49(12):1393-8. [Medline]. ... Diagnosis of mycosis fungoides with different algorithmic approaches. J Cutan Pathol. 2010 Jan. 37(1):8-14. [Medline]. ...
Opportunistic mycosis - definition of opportunistic mycosis by The Free Dictionary
opportunistic mycosis synonyms, opportunistic mycosis pronunciation, opportunistic mycosis translation, English dictionary ... definition of opportunistic mycosis. n. pl. my·co·ses 1. A fungal infection in or on a part of the body. 2. A disease caused by ... mycosis. (redirected from opportunistic mycosis). Also found in: Thesaurus, Medical, Encyclopedia. my·co·sis. (mī-kō′sĭs). n. ... mycosis. [maɪˈkəʊsɪs] n → micosi f. my·co·sis. n. micosis, cualquier enfermedad causada por hongos; ___ fungoide → ___ fungosa ...
PRIME PubMed | [Histoplasmosis and other imported mycoses in 1989]
Histoplasmosis and other imported mycoses in 1989]. Download Prime PubMed App to iPhone, iPad, or Android ... Systemic mycoses. 2. Systemic mycoses caused by dimorphous fungi (African histoplasmosis, blastomycosis, paracoccidioidomycosis ... Drouhet, E., & Dupont, B. (1989). [Histoplasmosis and other imported mycoses in 1989]. La Revue Du Praticien, 39(19), 1675-82. ... Drouhet E, Dupont B. [Histoplasmosis and Other Imported Mycoses in 1989]. Rev Prat. 1989 Sep 1;39(19):1675-82. PubMed PMID: ...
Cocci | Invasive Mycoses | Adult and Adolescent Opportunistic Infection | AIDSinfo
Unlike other endemic mycoses, Coccidioides grows relatively rapidly at 37°C on routine bacterial media, especially blood agar. ... Invasive Mycoses. Coccidioidomycosis. Last Updated: November 10, 2016; Last Reviewed: June 14, 2017 ... Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses. Clin Infect Dis. Aug 1 2016;63(3):356-362. Available at http ... The NIAID-Mycoses Study Group. Ann Intern Med. Jul 1 1993;119(1):28-35. Available at http://www.ncbi.nlm.nih.gov/pubmed/8498760 ...
Transformed Mycosis Fungoides - Lymphoma Research Foundation
Transformed Mycosis Fungoides occurs when a specific subset of MF tumor cells undergo molecular and/or genetic changes that ... Transformed Mycosis Fungoides. One of the most common forms of t-cell lymphoma is cutaneous T-cell lymphoma (CTCL), a general ... Transformed Mycosis Fungoides (TMF) is the most common type of CTCL, with approximately five cases per one million persons ... To learn more about transformed MF, download the Transformed Mycosis Fungoides Fact Sheet. ...
Bacterial Infections and Mycoses | GreenMedInfo | Disease | Natural
Diseases : Bacterial Infections and Mycoses. Problem Substances : Eszopiclone, Hypnotic Drugs, Ramelteon, Zaleplon, Zolpidem ( ... Diseases : Bacterial Infections and Mycoses, Celiac Disease. Additional Keywords : Diseases that are Linked, Diseases That ... Diseases : Bacterial Infections and Mycoses. Additional Keywords : Plant Extracts, The Whole is Superior to the Monochemical ... Diseases : Aspergillosis, Bacterial Infections and Mycoses, Fungal Infection. Pharmacological Actions : Anti-Bacterial Agents, ...
Treatment of superficial mycoses: review - part II
Mycoses. 2006;49:159-68. [ Links ] 31. Korting HC, Grundmann-Kollmann M. The hydroxypyridones: a class of antimycotics of its ... Mycoses. 2010;53:311-3. [ Links ] 35. Uchida K, Nishiyama Y, Yamaguchi H. In vitro antifungal activity of luliconazole (NND502 ... Mycoses. 1997;40:243-7. [ Links ] 32. Nenoff P, Haustein UF. In vitro susceptibility testing of Malassezia furfur against ... Superficial mycoses. In: Burns T, Breathnach S, Cox N, Griffiths C, editors. Rooks Textbook of Dermatology. 8th ed. New Jersey ...
HiDex User Reviews for Mycosis Fungoides at Drugs.com
List of Mycosis Fungoides Medications (17 Compared) - Drugs.com
Compare risks and benefits of common medications used for Mycosis Fungoides. Find the most popular drugs, view ratings, user ... Medications for Mycosis Fungoides. *Medication List. About Mycosis Fungoides: Mycosis fungoides is a low grade, non-Hodgkin ... Mycosis fungoides can progress from the skin to lymph nodes or internal organs. Mycosis fungoides is the most common subtype of ... Drugs Used to Treat Mycosis Fungoides. The following list of medications are in some way related to, or used in the treatment ...
mycosis fungoides Archives - NORD (National Organization for Rare Disorders)
Staging and prognosis of mycosis fungoides and Sézary syndrome
Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common subtypes of cutaneous T cell lymphoma (CTCL).MF is a mature ... Follicular mycosis fungoides. Am J Dermatopathol 1985; 7:300.. *Gerami P, Rosen S, Kuzel T, et al. Folliculotropic mycosis ... mycosis fungoides and Treatment of advanced stage (IIB to IV) mycosis fungoides.) ... Follicular mycosis fungoides. Br J Dermatol 1999; 141:137.. *Bonta MD, Tannous ZS, Demierre MF, et al. Rapidly progressing ...
Systemic Mycoses and Atypical Organisms | Washington Manual of Medical Therapeutics
Systemic Mycoses and Atypical Organisms answers are found in the Washington Manual of Medical Therapeutics powered by Unbound ... Systemic Mycoses and Atypical Organisms. In: Bhat PP, Dretler AA, Gdowski MM, et al, eds. Washington Manual of Medical ... "Systemic Mycoses and Atypical Organisms." Washington Manual of Medical Therapeutics, 35th ed., Wolters Kluwer Health, 2016. ... Systemic Mycoses and Atypical Organisms is a topic covered in the Washington Manual of Medical Therapeutics. To view the entire ...
Developing mycosis fungoidesSezary SyndromeLymphomaAssociated with mycosis fungoidesPouch mycosisEndemic mycosesPatient with mycosisDiagnosis of mycosisEarly stages of mycosis fungoidesFungiSuperficialCTCLOpportunisticManagement of mycosis fungoidesInfectionsClinicalCause systemic mycosesFolliculotropic Mycosis FungoidesAllergic Bronchopulmonary MycosisPatients with relapsedInvasiveDiseaseCutaneous T-cellCandidiasisTopical2020Lymph nodesTreat mycosisSystemic MycosisFungoides usuallyPulmonary mycosesProgression2018TherapeuticsAspergillosisLesionsCoccidioidesTreatmentCryptococcosisPrognosisTumorRefractorySubcutaneousSymptomsMedlinePlusInvolvementFungusPUVA
Developing mycosis fungoides1
- Certain variations of HLA genes may affect the risk of developing mycosis fungoides or may impact progression of the disorder. (medlineplus.gov)
Sezary Syndrome13
- Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). (medscape.com)
- PURPOSE: This phase II trial is studying temozolomide to see how well it works in treating patients with mycosis fungoides or Sezary syndrome that has not responded to previous treatment. (clinicaltrials.gov)
- Determine the response rate to temozolomide in patients with relapsed mycosis fungoides or Sezary syndrome. (clinicaltrials.gov)
- Submit your Twitter account related to Mycosis Fungoides And Sezary Syndrome to be featured! (novusbio.com)
- Submit your blog on Mycosis Fungoides And Sezary Syndrome to be featured! (novusbio.com)
- Research of Mycosis Fungoides And Sezary Syndrome has been linked to Mycoses, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-cell Lymphoma. (novusbio.com)
- The study of Mycosis Fungoides And Sezary Syndrome has been mentioned in research publications which can be found using our bioinformatics tool below. (novusbio.com)
- Researched pathways related to Mycosis Fungoides And Sezary Syndrome include Pathogenesis, Cell Activation, T Cell Activation, Glycosylation, Immunoglobulin Production. (novusbio.com)
- These pathways complement our catalog of research reagents for the study of Mycosis Fungoides And Sezary Syndrome including antibodies and ELISA kits against TSPYL2, IL2, CD4, SLC25A5, CD8A. (novusbio.com)
- Explore more on Mycosis Fungoides And Sezary Syndrome below! (novusbio.com)
- We have 3871 products for the study of Mycosis Fungoides And Sezary Syndrome that can be applied to Western Blot, Chromatin Immunoprecipitation, Flow Cytometry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry, Chromatin Immunoprecipitation (ChIP) from our catalog of antibodies and ELISA kits. (novusbio.com)
- OBJECTIVES: I. Determine the efficacy of tretinoin (TRA) in patients with mycosis fungoides/Sezary syndrome. (knowcancer.com)
- This study will investigate the safety and effectiveness of a modified donor stem cell transplantation procedure for treating advanced mycosis fungoides (MF), a lymphoma primarily affecting the skin, and Sezary syndrome (SS), a leukemic form of the disease. (clinicaltrials.gov)
Lymphoma19
- Mycosis fungoides is the most common form of a type of blood cancer called cutaneous T-cell lymphoma. (medlineplus.gov)
- Mycosis fungoides is the most common form of cutaneous T-cell lymphoma within the general population. (medscape.com)
- Mycosis fungoides (MF) is the most frequent type of primary cutaneous natural killer and T-cell lymphoma. (tripdatabase.com)
- Recommendations for treatment in Folliculotropic Mycosis Fungoides: Report of the Dutch Cutaneous Lymphoma Group. (tripdatabase.com)
- How is mycosis fungoides cutaneous T-cell lymphoma (CTCL) treated? (medscape.com)
- Mycosis fungoides is a low grade, non-Hodgkin lymphoma that arises in the skin and initially resembles eczema, dermatitis or psoriasis. (drugs.com)
- A biopsy was taken and I was told I had a rare form of lymphoma called cutaneous T-cell, mycosis fungoides. (rarediseases.org)
- Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common subtypes of cutaneous T cell lymphoma (CTCL). (uptodate.com)
- PubChem] The FDA granted marketing approval for the orphan drug Valchlor (mechlorethamine) gel on August 23, 2013 for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (CTCL) in patients who have received prior skin-directed therapy. (drugbank.ca)
- T-cell lymphoma of the ocular adnexa is rare, and when it occurs it is usually a manifestation of systemic T-cell lymphoma or represents a progression of mycosis fungoides (MF) on the skin [ 2 ]. (hindawi.com)
- Cases of T-cell lymphoma of the conjunctiva in patients with mycosis fungoides in the English literature. (hindawi.com)
- Mycosis fungoides (MF) is the most common type of cutaneous T cell lymphoma which manifests as patches, plaques, or nodules on non-sun exposed areas of the skin. (clinicaladvisor.com)
- A skin biopsy revealed the diagnosis of mycosis fungoides (patch stage, T1b N0 M0 B0), a most frequent cutaneous T-cell lymphoma. (medworm.com)
- Clinicopathological features of follicular mucinosis in the setting of hematopoietic stem cell transplantation and diverse systemic hematologic malignancies differ from mycosis fungoides-associated cases and follicular mucinosis is not necessarily a precursor to cutaneous T-cell lymphoma. (medworm.com)
- Mycosis fungoides (MF) is a low-grade cutaneous T cell lymphoma of unknown etiology. (pnas.org)
- SOLAR: A Phase 2, Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects with Cutaneous T-cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype. (clfoundation.org)
- Guidelines for phototherapy of mycosis fungoides and Sézary syndrome: a consensus statement of the United States Cutaneous Lymphoma Consortium. (springer.com)
- Local superficial radiotherapy in the management of minimal stage IA cutaneous T-cell lymphoma (Mycosis Fungoides). (springer.com)
- Mycosis fungoides (MF) is the most common type of cutaneous lymphoma and has protean clinicopathological manifestations. (biomedsearch.com)
Associated with mycosis fungoides4
- are associated with mycosis fungoides. (medlineplus.gov)
- Benign dermatopathic lymphadenopathy is associated with mycosis fungoides and often precedes lymphomatous infiltration. (biomedsearch.com)
- Immunotactoid glomerulopathy associated with mycosis fungoides. (bmj.com)
- We believe this is the first case reported of immunotactoid glomerulopathy associated with mycosis fungoides. (bmj.com)
Pouch mycosis3
- Guttural pouch mycosis is a fungal infection in the guttural pouch caused by a common fungi that most all horses carry. (k-state.edu)
- Horses affected by guttural pouch mycosis typically present for acute onset of voluminous hemorrhage from the nares. (k-state.edu)
- In horses, surgery to expose and remove fungal material has been used to treat guttural pouch mycosis. (merckvetmanual.com)
Endemic mycoses5
- Endemic mycoses remain a major public health problem in several countries and they are becoming increasingly frequent with the spread of HIV infection. (nih.gov)
- Amphotericin B remains the drug of choice during the acute stage of life-threatening endemic mycoses occurring in both immunocompetent and immunocompromised hosts. (nih.gov)
- Unlike other endemic mycoses, Coccidioides grows relatively rapidly at 37°C on routine bacterial media, especially blood agar. (nih.gov)
- Primary fungal laryngitis is commonly attributable to yeasts such as Candida , and Cryptococcus or fungi are known to cause endemic mycoses like Blastomyces, Paracoccidioides, and Coccidioides . (springer.com)
- On the other hand, endemic mycoses are caused by thermal-dimorphic fungi and can affect especially immunocompetent hosts that live in particular geographic areas, although immunosuppression is a risk factor and contributes to the outcome of infection ( Goughenour and Rappleye, 2017 ). (frontiersin.org)
Patient with mycosis2
- We report the case of a patient with mycosis fungoides who developed a progressive arthropathy from malignant synovial infiltration. (annals.org)
- A patient with mycosis fungoides developed a nephrotic syndrome. (bmj.com)
Diagnosis of mycosis2
- See 'Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides' and 'Clinical presentation, pathologic features, and diagnosis of Sézary syndrome' and 'Treatment of early stage (IA to IIA) mycosis fungoides' and 'Treatment of advanced stage (IIB to IV) mycosis fungoides' . (uptodate.com)
- A total of 4 points is required for the diagnosis of mycosis fungoides based on any combination of points from the clinical, histopathologic, molecular, and immunopathologic criteria. (clinicaladvisor.com)
Early stages of mycosis fungoides2
- In this study, 10 patients in the early stages of mycosis fungoides underwent clinical and lymphographical examinations. (biomedsearch.com)
- Thus, expect during the early stages of mycosis fungoides, there will be the appearance of lesions of which will be shown as scaly patches. (mffoundation.org)
Fungi4
- These are antibiotic or chemotherapeutic substances that act directly or indirectly on fungi and thus are of therapeutic use in mycoses. (scielo.br)
- Dimorphic fungi are agents of systemic mycoses associated with significant morbidity and frequent lethality in the Americas. (frontiersin.org)
- Distinct groups of fungi can cause systemic mycoses: geographically delimitated thermal-dimorphic fungi, classical yeast such as Cryptococcus spp. (frontiersin.org)
- Fungi & Systemic Mycoses Alfred Lewin References http://www.doctorfungus.org/ Schaechter et al. (powershow.com)
Superficial9
- The superficial mycoses. (nih.gov)
- The various agents of the superficial mycoses have been recognized for more than a century as causes of mild diseases affecting humankind. (nih.gov)
- The clinical manifestation, pathogenesis, and treatment of the common skin presentation of these and the other superficial mycoses are reviewed. (nih.gov)
- Superficial mycoses are limited to the outermost layers of the skin and hair. (wikipedia.org)
- Unlike the superficial mycoses, host immune responses may be evoked resulting in pathologic changes expressed in the deeper layers of the skin. (wikipedia.org)
- B35 Dermatophytosis B36 Other superficial mycoses B37 Candidiasis B38 Coccidioidomycosis B39 Histoplasmosis B40 Blastomycosis B41 Paracoccidioidomycosis B42 Sporotrichosis B43 Chromomycosis and pheomycotic abscess B44 Aspergillosis B45 Cryptococcosis B46 Zygomycosis B47 Mycetoma B48 Other mycoses, not elsewhere classified B49 Unspecified mycosis Keeping the skin clean and dry, as well as maintaining good hygiene, will help larger topical mycoses. (wikipedia.org)
- The first part of the article discusses the main treatments for superficial mycoses - keratophytoses, dermatophytosis, candidiasis, with a practical approach to the most commonly-used topical and systemic drugs , referring also to their dosage and duration of use. (scielo.br)
- 1 , 2 At the end of the 60's and 70's, the discovery of imidazole derivatives with antifungal activity was an important milestone in the treatment of superficial and deep mycoses, due to their high efficacy and low toxicity, as well as immunomodulatory activity. (scielo.br)
- The efficacy of topical agents in superficial mycoses depends not only on the type of lesion and the actual mechanism of action of the drug, but also on the viscosity, hydrophobicity and acidity of the formulation. (scielo.br)
CTCL3
- Transformed Mycosis Fungoides (TMF) is the most common type of CTCL, with approximately five cases per one million persons across the United States. (lymphoma.org)
- As the number of variants of CTCL has multiplied over the years, based on immunohistochemistry combined with morphology, certain subcategories, such as folliculotropic mycosis fungoides (FMF) have become well defined. (aad.org)
- Both mycosis fungoides and Sézary syndrome fall under the umbrella of cutaneous T-cell lymphomas (CTCL), a category of non-Hodgkin lymphomas that greatly impact the skin (cutaneous refers to the skin). (everydayhealth.com)
Opportunistic5
- citation needed] Systemic mycoses due to opportunistic pathogens are infections of patients with immune deficiencies who would otherwise not be infected. (wikipedia.org)
- Examples of opportunistic mycoses include Candidiasis, Cryptococcosis and Aspergillosis. (wikipedia.org)
- Aspergillosis, an opportunistic mycosis caused by the Aspergillus genus, affects mainly the respiratory system and is considered one of the most significant causes of mortality in captive penguins. (thefreedictionary.com)
- 1,2) Infection is believed to be less common than some of the other systemic mycoses mentioned in this paper, but is the third most frequent opportunistic mycosis in patients with neoplastic disease (1) as well as in ketoacidotic diabetics. (thefreedictionary.com)
- Microorganism Source material Opportunistic mycosis Candida albicans I hemoculture Candida albicans II urine culture MC Candida albicans III hemoculture 37203 Candida albicans IV hemoculture 37204 Candida albicans V hemoculture 15564 Candida albicans VI hemoculture 16655 Candida albicans VII hemoculture 1999 Candida glabrata I penis swab (candidemia by C. (thefreedictionary.com)
Management of mycosis fungoides3
- should be commended for their concise and useful review of the diagnosis and management of mycosis fungoides (MF). (cancernetwork.com)
- While the reader may expect a radiation oncologist's perspective on the management of mycosis fungoides, their review goes beyond highlighting the various radiation techniques used in the treatment of MF. (cancernetwork.com)
- Although the quality of life (QoL) plays an important role in treatment decision making and clinical management of mycosis fungoides (MF) or Sézary syndrome (SS) subtypes of cutaneous T-cell lymphomas (MF/SS-CTCLs), an MF- or SS-specific measure of QoL does not exist. (jmir.org)
Infections6
- It is possible that other factors, such as environmental exposure or certain bacterial or viral infections, are involved in the development of mycosis fungoides. (medlineplus.gov)
- Dermatophytes only cause infections of the skin, hair, and nails, and are unable to induce systemic, generalized mycoses, even in immunocompromised hosts. (wikipedia.org)
- Risk Factors for Skin Infections in Mycosis Fungoides. (tripdatabase.com)
- Mycosis infections are terrible diseases that can cause you an incredible skin irritation and even problems with your lungs and liver. (mffoundation.org)
- The growth of mycoses treatment market enhanced by the growing cases of fungal infections diseases and rise in research and development activities. (pharmiweb.com)
- Mycoses is infections caused by fungus that causes chronic diseases that's mainly affecting to skin, hair shaft and nails. (pharmiweb.com)
Clinical3
- Clinical staging and prognostic factors in folliculotropic mycosis fungoides. (aad.org)
- A retrospective study was performed to investigate the clinical features and associated factors of invasive mycoses (IM) in patients with connective tissue disease (CTD) from Southern China. (springer.com)
- On the clinical side, highlights were the development and implementation of improved diagnostic tests to better ascertain the public health burden of the AIDS-related mycoses, as well as development of and access to novel antifungal drugs and regimens suitable for resource-poor settings. (isham.org)
Cause systemic mycoses2
- Organisms that cause systemic mycoses are inherently virulent. (wikipedia.org)
- In general, primary pathogens that cause systemic mycoses are dimorphic[further explanation needed]. (wikipedia.org)
Folliculotropic Mycosis Fungoides2
- Folliculotropic mycosis fungoides (FMF) is an aggressive variant of mycosis fungoides (MF) and generally less responsive to standard skin-directed therapies (SDTs). (tripdatabase.com)
- New insights in to folliculotropic mycosis fungoides (FMF): A single center experience. (aad.org)
Allergic Bronchopulmonary Mycosis4
- How is Allergic Bronchopulmonary Mycosis abbreviated? (thefreedictionary.com)
- A rare case of allergic bronchopulmonary mycosis caused by Alternaria alternata," Medical Mycology, vol. (thefreedictionary.com)
- Pulmonary Cryptococcus neoformans infection of C57BL/6 mice is an established model of a chronic pulmonary fungal infection accompanied by an "allergic" response (T2) to the infection, i.e., a model of an allergic bronchopulmonary mycosis. (jimmunol.org)
- So, what is the role of IFN-γ in regulating the chronicity of the pulmonary infection in this murine model of allergic bronchopulmonary mycosis (ABPM)? (jimmunol.org)
Patients with relapsed1
- The FDA-approved mogamulizumab-kpkc, a CC chemokine receptor type 4 (CCR4)-directed mAb, in August 2018 for treatment of adult patients with relapsed or refractory mycosis fungoides or Sézary syndrome after at least one prior systemic therapy. (aacrjournals.org)
Invasive4
- citation needed] Cutaneous mycoses extend deeper into the epidermis, and also include invasive hair and nail diseases. (wikipedia.org)
- Finally, these non-culture-based tests can be used in combination to significantly increase the detection of invasive mycoses with the ultimate aim of establishing an early diagnosis of infection. (mdpi.com)
- 3)-beta-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. (nih.gov)
- 3)-beta-D-glucan with factor G is a highly sensitive and specific test for invasive deep mycosis and fungal febrile episodes, and will substantially benefit immunocompromised patients. (nih.gov)
Disease6
- Mycosis is an infectious disease caused by pathogenic fungus in humans and animals. (wikipedia.org)
- NIKOLA FIJAN "SYSTEMIC MYCOSIS IN CHANNEL CATFISH," Bulletin of the Wildlife Disease Association 5(2), 109-110, (1 April 1969). (bioone.org)
- Infection has been shown to function as a catalyst for further disease progression in mycosis fungoides, due to further activation of the defective immune system. (medscape.com)
- Mycosis Fungoides Foundation is a project that began some years ago to raise awareness about a disease that can develop and become something deadly, such as the fungus. (mffoundation.org)
- Leukemia was the major disease underlying the visceral mycoses, followed by solid cancers and other blood and hematopoietic system diseases. (asm.org)
- treatment of mycosis fungoides because of limited toxicity and the possibility of repeating treatments for long-term disease control. (osti.gov)
Cutaneous T-cell2
- Mycosis Fungoides (MF) and S ézary Syndrome (SS) are the most common types of primary cutaneous T cell lymphomas. (medworm.com)
- Cutaneous T cell lymphomas include a wide spectrum of lymphomas of which mycosis fungoides (MF) and Sézary syndrome are the most common representatives (reviewed in ref. 1 ). (pnas.org)
Candidiasis1
- As we reported previously, the total numbers of mycosis cases had been increasing until 1990, whereas the number of candidiasis cases had stopped increasing and had begun to decrease after 1989 ( 42 , 43 ). (asm.org)
Topical4
- citation needed] Topical and systemic antifungal drugs are used to treat mycoses. (wikipedia.org)
- Unilesional plantar mycosis fungoides treated with topical photodynamic therapy - case report and review of the literature. (tripdatabase.com)
- Case report: photo†onycholysis after PUVA treatment for hypopigmented mycosis fungoides with response to topical steroid Melanin in the nail bed in patients with skin type VI has been suggested to afford some protection against photo-onycholysis. (tripdatabase.com)
- A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. (medscape.com)
20203
- Mycoses Treatment Market 2020 Trends Analysis and Forecas. (pharmiweb.com)
- Pune, Maharashtra, India, June 23 2020 (Wiredrelease) Data Bridge Market Research - Mycoses Treatment Market report gives details about the market drivers and market restraints that help in knowing rise or fall of the demand of particular product with respect to market conditions. (pharmiweb.com)
- Global mycoses treatment market is expected to gain market growth in the forecast period of 2020 to 2027. (pharmiweb.com)
Lymph nodes4
- Coccidioidomycosis, strictly limited to the desertic regions in the western part of the American continent, is also a pulmonary mycosis with multiple granulomas in the skin, bones, lymph nodes and meninges. (unboundmedicine.com)
- Mycosis fungoides can progress from the skin to lymph nodes or internal organs. (drugs.com)
- TNMB criteria - The standard staging classification system for mycosis fungoides (MF) and Sézary syndrome (SS) is the TNMB system, which is based upon an evaluation of the skin (T), lymph nodes (N), visceral involvement (M), and blood (B) ( table 1A-B ) [ 1 ]. (uptodate.com)
- ICD-9 code 202.13 for Mycosis fungoides involving intra-abdominal lymph nodes is a medical classification as listed by WHO under the range -MALIGNANT NEOPLASM OF LYMPHATIC AND HEMATOPOIETIC TISSUE (200-208). (aapc.com)
Treat mycosis2
- written treatment guidelines for doctors who treat mycosis fungoides. (nccn.org)
- How I treat mycosis fungoides and Sézary syndrome. (medscape.com)
Systemic Mycosis2
- Antifungal therapy for systemic mycosis is limited, most of times expensive and causes important toxic effects. (frontiersin.org)
- In this review, we provide a discussion about conventional antifungal and nanoantifungal therapies for systemic mycosis. (frontiersin.org)
Fungoides usually2
- Mycosis fungoides usually occurs in adults over age 50, although affected children have been identified. (medlineplus.gov)
- Mycosis fungoides usually impacts people older than 40, and Sézary syndrome most often develops in individuals older than 60. (everydayhealth.com)
Pulmonary mycoses1
- Blastomycosis, imported from North America as well as from North Africa and Central Africa, and paracoccidioidomycosis, imported from Latin America, are pulmonary mycoses with cutaneous manifestations on the face and extremities and with various deep localizations which often follow a chronic course. (unboundmedicine.com)
Progression2
- Expression dynamics of CXCL12 and CXCR4 during the progression of mycosis fungoides. (sigmaaldrich.com)
- Unilesional follicular mycosis fungoides: report of two cases with progression to tumor stage and review of the literature. (biomedsearch.com)
20181
- Hypopigmented Mycosis Fungoides Treated with 308 nm Excimer Laser 29386841 2018 11 13 1013-9087 30 1 2018 Feb Annals of dermatology Ann Dermatol Hypopigmented Mycosis Fungoides Treated with 308 nm Excimer Laser. (tripdatabase.com)
Therapeutics7
- Systemic Mycoses and Atypical Organisms is a topic covered in the Washington Manual of Medical Therapeutics . (unboundmedicine.com)
- Identify and understand important and diverse types of therapeutics under development for Mycoses. (sbwire.com)
- Devise corrective measures for pipeline projects by understanding Mycoses pipeline depth and focus of Mycoses therapeutics. (sbwire.com)
- The analyst has been monitoring the mycosis fungoides therapeutics market and it is poised to grow by $ 115.42 mn during 2021-2025, progressing at a CAGR of 5% during the forecast period. (reportbuyer.com)
- Our report on mycosis fungoides therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. (reportbuyer.com)
- The mycosis fungoides therapeutics market analysis includes type segment and geographical landscapes. (reportbuyer.com)
- This study identifies the strong R&D of pipeline molecule as one of the prime reasons driving the mycosis fungoides therapeutics market growth during the next few years. (reportbuyer.com)
Aspergillosis1
- Aspergillosis cases were not decreasing but maintained the highest rate of mycosis among the total autopsies. (asm.org)
Lesions4
- Consider systemic mycoses in normal hosts with unexplained chronic pulmonary pathology, chronic meningitis, lytic bone lesions, chronic skin lesions, FUO, or cytopenias. (unboundmedicine.com)
- The presence of human herpesvirus 8 (HHV-8) - associated with all forms of Kaposi's sarcoma - has also been recently identified in mycosis fungoides lesions. (scielo.br)
- The present case reports a patient who developed Kaposi's sarcoma lesions after a two-year UVB phototherapy to treat a mycosis fungoides. (scielo.br)
- Negative immunohistochemistry staining for Kaposi's sarcoma-associated herpesvirus in the initial mycosis fungoides lesions strengthens the absence of a link between Kaposi's sarcoma-associated herpesvirus and mycosis fungoides. (scielo.br)
Coccidioides1
- Among the causative agents of endemic mycosis are Histoplasma capsulatum, Coccidioides immitis and C. posadasii, Paracoccidioides brasiliensis , and P. lutzii, Blastomyces dermatitidis, Talaromyces marneffei , and Sporothrix schenckii . (frontiersin.org)
Treatment13
- This book focuses on the treatment of mycosis fungoides. (nccn.org)
- We report a case of a 16-year-old male patient with skin type VI with onycholysis following PUVA treatment for hypopigmented mycosis fungoides . (tripdatabase.com)
- Successful use of allogeneic stem cell transplantation for treatment-refractory mycosis fungoides]. (medscape.com)
- Aspergillus PCR has been extensively validated with standardized approaches established for these methods and will be included in the diagnostic criteria in the revised European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC-MSG) definitions. (mdpi.com)
- Major topics discussed were epidemiology and public health, improving diagnosis, host-pathogen interactions, immunology, drug resistance, treatment strategies, new antifungal drugs and vaccines for the major AIDS-related mycoses including cryptococcosis, pneumocystosis, histoplasmosis and penicilliosis. (isham.org)
- A Mycosis Fungoides, Familial anonymous support group with information on diagnosis, treatment, symptoms, along with personal stories and experiences with Mycosis Fungoides, Familial. (experienceproject.com)
- Purpose: To determine the effect of low-dose (4 Gy) total skin electron beam therapy as a second-line treatment of Stage IB-II mycosis fungoides in a prospective, open-label study. (osti.gov)
- Methods and Materials: Ten patients (6 men, 4 women, average age 68.7 years [range, 55-82 years]) with histopathologically confirmed mycosis fungoides T2-T4 N0-N1 M0 who did not achieve complete remission or relapsed within 4 months after treatment with psoralen plus ultraviolet-A were included. (osti.gov)
- Strategic aspects of the Pharmaceutical industry such as product development and specification, technology, niche growth opportunities, application modelling, and new geographical markets can be undertaken with the vast information and data included in this Mycoses Treatment Market report. (pharmiweb.com)
- Moreover, advances in the drug formulation such as fixed dose combination and cost-effective treatment are some of the impacting factors for the demand of mycoses treatment. (pharmiweb.com)
- This mycoses treatment market report provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographical expansions and technological innovations in the market. (pharmiweb.com)
- The National Comprehensive Cancer Network (NCCN) has created guidelines for the treatment and staging of mycosis fungoides. (springer.com)
- Ahmad K, Rogers S, McNicholas PD, Collins P. Narrowband UVB and PUVA in the treatment of mycosis fungoides: a retrospective study. (springer.com)
Cryptococcosis2
- Pal M, Dave P (2016) Cryptococcosis: An Emerging Airborne Mycosis of Global Concern. (omicsonline.org)
- Cryptococcosis, an emerging highly infectious respiratory mycosis, is mainly caused by Cryptococcus neoformans and Cryptococcus gattii, which exist as saprobe in the environment. (omicsonline.org)
Prognosis1
- Extracutaneous manifestations of mycosis fungoides imply a bad prognosis and are a major cause of death. (biomedsearch.com)
Tumor1
- Spread to other organs can occur in any stage of mycosis fungoides but is most common in the tumor stage. (medlineplus.gov)
Refractory2
- Photodynamic Therapy in Treating Patients With Refractory Mycosis Fungoides Photodynamic Therapy in Treating Patients With Refractory Mycosis Fungoides - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. (tripdatabase.com)
- Photodynamic Therapy in Treating Patients With Refractory Mycosis Fungoides The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. (tripdatabase.com)
Subcutaneous1
- Subcutaneous mycoses involve the dermis, subcutaneous tissues, muscle and fascia. (wikipedia.org)
Symptoms1
- The symptoms of mycoses depend on the degree of tissue involvement. (pharmiweb.com)
MedlinePlus1
- 3) And mycosis fungoides (also called Alibert-Bazin syndrome or granuloma fungoides) is slow-moving and develops over several years, notes MedlinePlus. (everydayhealth.com)
Involvement2
- Mycosis fungoides (MF) classically presents from patch stage to plaque stage over a number of years and finally progresses to tumour stage with nodal or visceral involvement. (sigmaaldrich.com)
- Gül U, Soylu S, Aslan E, Yazar Z, Demiriz M. Uncommon presentation of mycosis fungoides: eyelid margin involvement. (springer.com)
Fungus1
- Mycosis fungoides was so named because the tumors can resemble mushrooms, a type of fungus. (medlineplus.gov)
PUVA3
- PUVA-induced suppression of contact sensitivity to mustine hydrochloride in mycosis fungoides. (bmj.com)
- Volden G , Molin L , Thomsen K . PUVA-induced suppression of contact sensitivity to mustine hydrochloride in mycosis fungoides. (bmj.com)
- Determine if ultraviolet A light therapy with methoxsalen (PUVA) with or without bexarotene yields a significantly higher overall response rate in patients with mycosis fungoides. (knowcancer.com)